Daiichi Sankyo Shares Jump
Daiichi Sankyo Shares Jump After U.S. FDA Approves Breast Cancer Drug
Daiichi Sankyo shares rose sharply after the U.S. Food and Drug Administration approved its breast cancer drug Datroway. Shares were recently 8.7% higher at 4,437 yen, equivalent to $28.39, on Monday after rising as much as 9.7% earlier. Over the past three years, the stock posted a daily gain of more than 8% only four times.
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
AstraZeneca AZN announced that the FDA has approved its antibody-drug conjugate (ADC), datopotamab deruxtecan (or Dato-DXd), ...
Following a world-first approval in Japan, AstraZeneca and Daiichi Sankyo’s second antibody-drug conjugate has crossed the ...
Daiichi Sankyo Company, Ltd (TSE: 4568) announced today that it will pay Glycotope $132.5 million to acquire intellectual ...
Daiichi Sankyo has finalised the acquisition of intellectual property rights for gatipotuzumab, an anti-tumour-associated ...
Daiichi Sankyo to pay $132.5 million to acquire IP rights for anti-TAMUC1 antibody in DS-3939 from Glycotope: Tokyo Wednesday, January 15, 2025, 09:00 Hrs [IST] Daiichi Sankyo Com ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback